Poster presentations at IMS 2026 highlighted the use of venetoclax, daratumumab, and different combination regimens across ...
The second FACE-OFF debate explores whether currently available BCMA bispecific antibodies should be considered a therapeutic class or whether meaningful clinical differences exist among individual ...
The American Society of Hematology (ASH) released guidelines on frontline management of acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs), as well as the management of relapsed ...
In August 2012, Janssen Biotech, Inc. and Genmab A/S entered a worldwide agreement, which granted Janssen an exclusive license to develop, manufacture and commercialize daratumumab. For more ...
Multiple myeloma treatment typically follows a pathway starting with induction therapy (a combination of three to four drugs), followed by autologous stem cell transplant (ASCT) if eligible, then ...
Analysis showed ~87% of patients treated with TECVAYLI®▼ plus daratumumab as early as second line were estimated to have comparable mortality risk to the general population1A separate analysis shows ...
For patients with Waldenström macroglobulinemia whose disease returns after standard treatments, the therapeutic arsenal has ...
Durability metrics included median duration of response 29.1 months and median PFS 30.2 months, with ongoing responses ...
Treating patients with CAR-T cell therapy Breyanzi may change the paradigm for those with relapsed or refractory mantle cell lymphoma, an expert said. Treatment with CAR-T cell therapy Breyanzi ...
Johnson & Johnson (NYSE:JNJ) announced new data from the Phase 3 MajesTEC-3 study showing sustained disease control and survival with TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results